COVID-19 Surge Returns to US; New Variant Drives West Coast Spike

The virus is back. Not in the way it was in 2020, when the world stopped and held its breath, but in a quieter, more persistent way—the kind of return that catches people mid-summer, when they've stopped thinking about masks and testing and whether they should reschedule that trip. Across the United States, COVID-19 cases are climbing again, and this time a mutated strain appears to be driving the surge, particularly along the West Coast.

The variant, which researchers have nicknamed the "Cicada" variant, has become the focal point of a summer wave that's showing up first in wastewater data before it shows up in hospital admissions. In the San Francisco Bay Area, multiple communities are registering elevated virus levels in their sewage systems—a leading indicator that infections are spreading through the population, often before people even know they're sick. The wastewater signal is sensitive enough to catch what's happening before traditional case counts do, which means public health officials are watching the data closely as it unfolds.

What makes this surge different from previous waves is how it's distributed. Rather than a uniform spike across the country, the West Coast is experiencing the most pronounced increase, suggesting the Cicada variant may have particular advantages in spreading through that region's population. Whether that's due to travel patterns, population density, or the variant's own characteristics remains under investigation, but the geographic concentration is notable enough that health authorities are paying specific attention to California and surrounding states.

The good news, if there is good news in a resurgent pandemic, is that the toolkit for managing COVID-19 has expanded considerably since the early days of the virus. Updated vaccines are available and recommended, particularly for people at higher risk of severe illness. Paxlovid, the antiviral treatment that can reduce the severity of infection if taken early, remains an option for those who do get sick. A newer treatment called Xocova has also entered the arsenal. For pregnant individuals, who face particular risks from COVID-19, there is specific guidance on which preventive measures and treatments are safest to use.

The challenge now is less about whether tools exist and more about whether people will use them. The pandemic fatigue that set in years ago hasn't disappeared, and many Americans have moved on psychologically from thinking about COVID-19 as an active threat. A summer surge, even one driven by a new variant, doesn't carry the same urgency it once did. People are traveling, gathering, returning to offices. The virus, meanwhile, is doing what viruses do: mutating and spreading through populations that have lower immunity than they did a few years ago, either because vaccination rates have declined or because immunity from previous infections has waned.

Public health officials are monitoring the situation closely, watching both the wastewater data and clinical case reports to understand how quickly the Cicada variant is spreading and whether it's causing more severe illness than previous strains. The forward-looking question is whether this summer surge will remain contained to the West Coast or whether it will eventually spread eastward as the season progresses. That answer will likely determine how much attention the surge receives and whether it prompts a broader public health response or remains a regional concern managed quietly by local health departments and individual choice.